In 2007, medical researchers discovered Bio 30 propolis suppresses the growth of human neurofibromatosis tumours in mice.

Melbourne-based cancer researcher Professor Hiroshi Maruta led a German research team which identified the first known anti-cancer ingredient in propolis — caffeic acid phenethyl ester (CAPE), a natural compound highly concentrated in Bio 30 propolis.

The following year Dr Maruta’s researchers tested Bio 30 propolis on 70 neurofibromatosis, melanoma and pancreatic cancer sufferers.

The research team reported Bio 30 propolis halted tumour growth, with most patients showing no further growth in their tumours.

Neurofibromatosis (NF) is a set of genetic disorders which cause tumours to grow along various types of nerves and can affect the development of non-nervous tissue such as bone and skin. In severe cases the disorder affects nerves throughout the body, including the brain and spinal cord.

The Bio 30 propolis liquid used in the trial contained 30 mg/g of bioflavonoids, a natural substance which has anti-oxidant, anti-bacterial, anti-viral and antiseptic properties.

Bio 30 propolis is three times more effective than Brazilian green propolis, which was previously regarded as the world-leading anti-cancer propolis. Bio 30 propolis is only 10% of the price of the green propolis.

Daily treatment of an adult NF patient weighing around 50kg requires 5ml of Bio 30 propolis. Bio 30 propolis shows no side effects at this dose, except that 1% of the population is known to be allergic to the CAPE-based propolis.

At a cost of a dollar a day for each patient Bio 30 propolis is economically quite feasible even for a life-long treatment of both NF1 and NF2 tumors.

Patients with cancers may only use Bio 30 propolis for a period but even when cleared are likely to continue to use it on a maintenance basis to prevent cancer recurrence.

For detailed information about other cancers and illnesses which can be treated by the CAPE compound in Bio 30 propolis see The Science section.